NCT03995108Phase 3Completed

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Study sponsor: X4 Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-12-23Actual
Enrollment · participants31Actual
Source updated2026-07-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2025. After: 23 Dec 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview